Antibiotics in the management of hepatic encephalopathy: An evidence-based review

Reviews in Gastroenterological Disorders

Volumn 5, Issue SUPPL. 3, 2005, Pages

  Rothenberg, Michael E ^a   Keeffe, Emmet B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatic encephalopathy; Metronidazole; Minimally absorbed antibiotics; Neomycin; Rifaximin; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; CYTOCHROME P450; DISACCHARIDE; LACTULOSE; METRONIDAZOLE; NEOMYCIN; NEUROTOXIN; PLACEBO; RIFAXIMIN; VANCOMYCIN;

ANOREXIA; ARTICLE; ATAXIA; CLINICAL TRIAL; DIAPHORESIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ENTEROCOLITIS; EVIDENCE BASED MEDICINE; FLUSHING; HEART PALPITATION; HEPATIC ENCEPHALOPATHY; HOSPITAL INFECTION; HUMAN; INFECTION RISK; INTERMETHOD COMPARISON; INTESTINE FLORA; MENTAL DISEASE; META ANALYSIS; METHODOLOGY; MORBIDITY; MORTALITY; MUSCLE CRAMP; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PREVALENCE; PRURITUS; RISK ASSESSMENT; RISK REDUCTION; SEIZURE; SEPSIS; SIDE EFFECT; SYMPTOMATOLOGY; VANCOMYCIN RESISTANT ENTEROCOCCUS; VERTIGO; VOMITING;

ANTI-BACTERIAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; TREATMENT OUTCOME;

EID: 31144444258     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Schomerus H, Hamster W, Blunck H, et al. Latent portasystemic encephalopathy. 1. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci. 1981;26:622-630.
2. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28:45-49.
3. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/HCUPnet/
4. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-721.
5. Wolpert E, Phillips SF, Summerskill WH. Transport of urea and ammonia production in the human colon. Lancet. 1971;2:1387-1390.
6. Wolpert E, Phillips SF, Summerskill WH. Ammonia production in the human colon: effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med. 1970;283:159-164.
7. Dawson AM, McLaren J, Sherlock S. Neomycin in the treatment of hepatic coma. Lancet. 1957;273:1262-1268.
8. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial. Gastroenterology. 1977;72:573-583.
9. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Systematic Rev. 2004; 2:CD003044
10. Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology. 1987;7:639-643.
11. Orlandi F, Freddara U, Candelaresi MT, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci. 1981;26: 498-506.
12. Tinmouth JM, Steele LS, Tomlinson G, Glazier RH. Are claims of equivalency in digestive diseases trials supported by the evidence? Gastroenterology. 2004;126:1700-1710.
13. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328:1046.
14. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968-1976.
15. Sanaka MR, Ong JP, Mullen KD. Challenges of designing hepatic encephalopathy treatment trials. Hepatology. 2003;38:527-528.
16. Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ. Central nervous system toxicity associated with metronidazole therapy. Ann Intern Med. 1980;93:59-60.
17. Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut. 1982;23:1-7.
18. Tarao K, Ikeda T, Hayashi K, et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut. 1990;31:702-706.
19. McCullough JM, Dielman DG, Peery D. Oral vancomycin-induced rash: case report and review of the literature. DICP. 1991;25:1326-1328.
20. Torres-Viera C, Dembry LM. Approaches to vancomycin-resistant enterococci. Curr Opin Infect Dis. 2004;17:541-547.
21. Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology. 1992;39:542-545.
22. Blanc P, Daures JP, Liautard J, et al. Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy: Results of a randomized controlled trial [in French]. Gastroenterol Clin Biol. 1994;18:1063-1068.
23. Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord. 2005;5:19-30.
24. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multicentre study. Eur J Gastroenterol Hepatol. 2000; 12:203-208.
25. Bass NM, Ahmed A, Johnson L, Gardner JD. Rifaximin treatment is beneficial for mild hepatic encephalopathy. Poster presented at the Liver Meeting™. October 29-November 2, 2004; Boston, MA.
26. Simmons F, Goldstein H, Boyle JD. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology. 1970;59:827-832.
27. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38:51-58.
28. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy: a double-blind, randomised trial. Curr Med Res Opin. 1997;13:593-601.
29. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993;13:109-118.
30. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol. 1991;23:175-178.
31. Massa P VE, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res. 1993;4:7-18.
32. Giacomo F, Michele N, Oronzo S, Antonella F. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res. 1993;4:57-66.
33. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet. 2005;365:431-433.